Do Parasites Harbor Bacteria and Viruses?

Table of Contents

1. What the Presentation Said
2. Three Ways a Parasite Can "Carry" Another Germ
3. Blood Flukes and Long-Lasting Salmonella Infection
4. Trichomonas: A Parasite With Its Own Bacteria and Viruses
5. Acanthamoeba: An Amoeba That Shelters Bacteria
6. Filarial Worms and Their Wolbachia Bacteria
7. Strongyloides: Worms That Carry Gut Bacteria Into the Blood
8. Worm Co-Infection With Human Immunodeficiency Virus and Tuberculosis
9. Is There Research on Treating Parasites First?
10. How the Claim Compares With the Research
11. What Is Not Known
12. Connections
13. Key Research Papers
14. Featured Videos

What the Presentation Said

The presentation was a 2026 webinar given by the medical director of an integrative cancer clinic. Early in the talk the speaker said that parasites harbor toxins and pathogens (disease-causing germs), creating what was described as a toxic sink, and that in a person with cancer, parasites are part of the tumor microenvironment, meaning the mix of cells, blood vessels and microbes around a tumor.

Later the speaker returned to the idea with a practical rule. The points made were:

• when a patient has viruses, mold, bacteria and parasites at the same time, the parasites are to be dealt with first;
• the reason given was that parasites harbor viruses, bacteria and heavy metals, so treating the viruses first would not reach all of them;
• treating parasites first, with the body's routes of elimination kept open, was said to give better results, both against the parasites and against viruses;
• parasites, viruses and bacteria were described as companions that stay together, and parasites were said to release secretions, distort cell signals, block oxygen and poison the terrain in which cancer forms.

The speaker did not cite a study for the treatment order and did not name a particular parasite, bacterium or virus. This page therefore tests the general claim against the best-studied real examples of parasites that carry, shelter or help other germs. Heavy metals are covered on a separate page, Parasites and Heavy Metals, and the partnership between malaria and the Epstein-Barr virus in a childhood cancer is covered on Malaria and Burkitt Lymphoma.

Three Ways a Parasite Can "Carry" Another Germ

The word "harbor" covers several quite different situations in the research. Keeping them apart makes the evidence easier to follow.

1. Germs living inside the parasite

Some single-celled parasites and some worms carry bacteria or viruses inside their own cells. Biologists call these passengers endosymbionts ("living together inside"). The relationship can be stable for generations, and the passenger can change how the parasite behaves or responds to drugs. Trichomonas, Acanthamoeba and the filarial worms below are the clearest examples.

2. Germs that use the parasite as a route or a shelter

Some bacteria survive inside amoebae in water pipes and soil, protected from disinfectants, and reach people that way. Worm larvae moving out of the gut can carry gut bacteria with them into the bloodstream.

3. Co-infection, where one infection changes the body's defenses

Here the parasite does not carry anything. Instead, being infected with a worm or a fluke changes the immune system or damages tissue, so that a second infection (Salmonella, human immunodeficiency virus (HIV), tuberculosis) behaves differently. Much of what is loosely described as parasites "harboring" viruses falls into this third group.

Blood Flukes and Long-Lasting Salmonella Infection

Schistosomes are flatworms that live in the blood vessels around the gut or bladder (see Schistosoma). Doctors working in Egypt and Brazil in the twentieth century described patients with schistosomiasis whose Salmonella infections (typhoid and related fevers) kept coming back, with the bacteria repeatedly appearing in the blood or urine.

• A 2000 review from Brazil of the illness caused by Schistosoma mansoni lists an "association with Salmonella" among the recognized complications of the infection, alongside associations with Staphylococcus bacteria and hepatitis B. The authors expected Salmonella bloodstream infection to be one of the problems that would fall quickly once schistosomiasis was controlled (Lambertucci and colleagues, 2000).
• A 1975 study in Egypt treated 12 patients who had proven Salmonella typhi or Salmonella paratyphi A in the urine and recurrent bacteria in the blood, associated with schistosomiasis. They received the antibiotic amoxicillin, 250 mg four times a day, for four weeks. Seven had been seriously ill and feverish; they became fever-free within three to six days. Within one week all blood and urine samples were negative for Salmonella and stayed negative through the four-week hospital follow-up (Farid and colleagues, 1975).

Two points stand out. The pairing of a worm infection with a stubborn bacterial infection is real and was described in human patients. But in the one treatment study in this set, an antibiotic alone cleared the bacteria during the follow-up period; the abstract does not report a longer follow-up or a comparison with treating the worm first. The bladder-cancer side of this parasite is covered on Schistosoma and Bladder Cancer.

Trichomonas: A Parasite With Its Own Bacteria and Viruses

Trichomonas vaginalis is a single-celled parasite that causes trichomoniasis, described in the research as the most common sexually transmitted infection that is not caused by a virus. It is the best-documented case of a human parasite that carries both bacteria and viruses inside its cells.

Mycoplasma bacteria inside the parasite

• Reviews from a research group in Sardinia describe Mycoplasma hominis, a small bacterium of the genital tract, living and multiplying inside the parasite's cell. In laboratory work, the parasite passed the bacterium both to Mycoplasma-free parasites and to human cells (Dessì and colleagues, 2019).
• A 2023 review from the same group calls this pairing the only known example of an endosymbiosis (one living inside the other) between two true human pathogens. The bacterium makes the parasite more aggressive toward human cells and triggers a stronger inflammatory response. A second, newly found bacterium, Candidatus Mycoplasma girerdii, also lives with the parasite (Margarita and colleagues, 2023).
• A laboratory study from Vienna reported that up to 90% of Trichomonas strains isolated in Europe carry Mycoplasma hominis naturally. In cell culture, the bacterium switched down parasite genes linked to sensitivity to metronidazole, the usual treatment, and roughly doubled the drug concentration the parasite could tolerate in three strains (Fürnkranz and colleagues, 2018). This is laboratory work, not a clinical finding.
• A 2025 laboratory study in host-cell cultures found that the bacterium (with or without the parasite) set off a defensive signal called interferon-epsilon, and that tiny packets the parasite releases (extracellular vesicles) dampened that signal, helping the infection along (Kochanowsky and colleagues, 2025).

Viruses inside the parasite

• Trichomonas can also carry up to four double-stranded RNA viruses, known together as Trichomonas vaginalis virus (Margarita and colleagues, 2020). The research describes these viruses as infecting the parasite itself; none of the studies read for this page describes them infecting human cells.
• A 2025 review describes the virus altering parasite proteins linked to virulence and immune evasion, and notes that parasite isolates without the virus are more likely to resist metronidazole (Graves and colleagues, 2025).
• In parasites grown from 355 women in Alabama, the virus was found in 40%. The study found no link between the virus and symptoms, repeat infections or metronidazole resistance, and the authors suggested the virus may be a harmless passenger of the parasite (Graves and colleagues, 2019).

So Trichomonas really does harbor bacteria and viruses. But the research does not show that these passengers are viruses that cause disease in people, and one human study found the virus made no measurable clinical difference. Trichomoniasis itself is linked in the research with a higher risk of acquiring human immunodeficiency virus (Margarita and colleagues, 2020), which is a co-infection effect rather than the parasite carrying human immunodeficiency virus.

Acanthamoeba: An Amoeba That Shelters Bacteria

Acanthamoeba is a free-living amoeba found in soil, tap water and swimming pools. It feeds on bacteria, but some bacteria have evolved to survive and even multiply inside it.

• A 2004 review lists established human pathogens that resist being digested by free-living amoebae, including Legionella (the cause of Legionnaires' disease), Chlamydophila pneumoniae, Mycobacterium avium, Listeria monocytogenes, Pseudomonas aeruginosa and the fungus Cryptococcus neoformans. The authors describe amoebae as a possible "Trojan horse": while they are in their tough resting form (cysts), they may protect the bacteria inside from chlorine and other disinfectants, and they can release vesicles filled with bacteria (Greub and Raoult, 2004).
• In 37 Acanthamoeba isolates taken from 23 patients with Acanthamoeba keratitis (an eye infection usually linked to contact lenses) and one environmental sample, 22 of 38 cultures (59.4%) contained at least one bacterial endosymbiont from the genera Legionella, Pseudomonas, Mycobacterium or Chlamydia. Isolates with bacteria inside were more damaging to corneal cells in the laboratory, and there was a trend, not statistically significant, toward worse initial vision in those patients (Iovieno and colleagues, 2010).
• In a laboratory experiment on agar plates, one Acanthamoeba strain carrying a Neochlamydia bacterium could "backpack" E. coli and Salmonella and move them across the plate, which the same amoeba without its symbiont could not do (Okubo and colleagues, 2018). This is a dish experiment, not a finding in people.

This is the clearest case in which a parasite acts as a carrier and shelter for bacteria. It matters mostly for water systems and for contact-lens eye infections. No research was found that links it to cancer.

Filarial Worms and Their Wolbachia Bacteria

Filarial worms are thread-like worms spread by insects. They cause lymphatic filariasis (Wuchereria bancrofti) and river blindness (Onchocerca). Most of these species carry bacteria called Wolbachia inside their own cells, and the worms depend on them.

This is the one area where randomized trials in people have tested what happens when the passenger is treated, and the order is the reverse of the presentation's rule: an antibiotic aimed at the bacteria is used to harm the worm.

• In a placebo-controlled trial in 57 men in Orissa, India, with bancroftian filariasis, 21 days of doxycycline (200 mg a day) cut Wolbachia in the worms by 94% before a single dose of the antiworm drug diethylcarbamazine was given four months later. At 12 months, all men in the 21-day group had no microfilariae (worm larvae) in the blood, and the swollen lymph vessels in the scrotum had shrunk, which was not seen in the other groups (Mand and colleagues, 2009).
• In an open-label randomized trial in Mali of 216 people with Mansonella perstans, a filarial worm that does not respond well to standard antiworm drugs, 6 weeks of doxycycline (200 mg a day) left 67 of 69 treated people (97%) with no detectable microfilariae at 12 months, against 10 of 63 untreated people (16%). Vomiting was more common with doxycycline (17% against 4%) (Coulibaly and colleagues, 2009).

These trials show that a parasite's own bacteria can be a real target. They do not support treating a worm before its bacteria; for these worms the published approach goes the other way.

Strongyloides: Worms That Carry Gut Bacteria Into the Blood

Strongyloides stercoralis is a small roundworm that can reinfect the same person from inside the gut for decades. When the immune system is suppressed, especially by corticosteroid medicines, the number of larvae can explode and they spread through the body. This is called hyperinfection (see Hyperinfection and Dissemination).

The larvae pass out through the wall of the gut, and gut bacteria travel with them. That is why bloodstream infection with gut bacteria (Gram-negative bacteria such as E. coli, and enterococci) is one of the hallmarks of hyperinfection.

• A French review lists severe gut and lung involvement, meningitis, skin rash and Gram-negative bacteremia (bacteria in the blood) as features of disseminated strongyloidiasis, which it describes as fatal in 80% of cases (Nozais and colleagues, 2001).
• A review of 108 episodes in organ and stem-cell transplant recipients found bacteremia in 31 of 59 episodes with data (52.5%), most often Gram-negative (24 of 31). All-cause death was 44.9%, and death attributed to Strongyloides was 65.3% (Abad and colleagues, 2022).
• Case reports describe hyperinfection with Gram-negative bloodstream infection after a single 8 mg dose of dexamethasone given to mature a baby's lungs before delivery; the woman recovered after ivermectin and albendazole (Meisenheimer and colleagues, 2023). Another describes a woman with chronic lymphocytic leukemia on intermittent steroids whose hyperinfection was followed by enterococcal blood infection and meningitis; she died (Najmuddin and colleagues, 2012).

A virus that makes the worm worse

The virus HTLV-1 (human T-cell lymphotropic virus type 1) is found in the same regions as Strongyloides. A 2022 systematic review and meta-analysis of 14 studies found that people with HTLV-1 had higher odds of Strongyloides infection (odds ratio 3.2), much higher odds of severe strongyloidiasis (odds ratio 59.9) and higher odds of treatment failure (odds ratio 5.05). The authors concluded that screening for each infection be routine when the other is diagnosed (Ye and colleagues, 2022). Here the virus is the factor that makes the parasite more dangerous, not the other way round.

Worm Co-Infection With Human Immunodeficiency Virus and Tuberculosis

Worm infections are common where human immunodeficiency virus and tuberculosis are common. Researchers have asked whether the worms change the course of these diseases, and whether deworming helps.

Human Immunodeficiency Virus

• In a rural Zimbabwean community, 527 women were examined. Women with Schistosoma haematobium lesions of the genital tract (female genital schistosomiasis) had almost three times the odds of having human immunodeficiency virus (adjusted odds ratio 2.9). The study was cross-sectional, and the authors called for prospective studies to confirm the link (Kjetland and colleagues, 2006).
• A 2009 Cochrane review pooled three randomized trials in people with both human immunodeficiency virus and worm infections and found benefit from deworming on human immunodeficiency virus viral load and CD4 counts (a measure of immune strength) (Walson and colleagues, 2009).
• The 2016 update of the same Cochrane review, with eight trials and 1,612 participants, was more cautious. Treating confirmed worm infections in adults with human immunodeficiency virus may have a small, short-term favorable effect on viral load (low-quality evidence, strongly influenced by one praziquantel trial). Deworming every three months for two years in people whose worm status was unknown probably had little or no effect on viral load or CD4 count. No added harm was seen, though side effects were poorly reported (Means and colleagues, 2016).

Tuberculosis

A 2012 review describes strong experimental evidence that worm infections push the immune system toward responses that weaken defense against tuberculosis bacteria. It also notes that treating mothers for worms did not change their infants' response to the BCG tuberculosis vaccine, and states that whether worms affect tuberculosis disease in people is still an open question (Rafi and colleagues, 2012).

In co-infection, then, the worm changes the immune setting; it does not carry the virus or bacterium. The measured benefit of deworming on human immunodeficiency virus markers is small and uncertain.

Is There Research on Treating Parasites First?

For this page, PubMed was searched for clinical trials comparing treatment of parasites before, after or alongside treatment of viral, bacterial or fungal infections. No trial was found that tested a general "parasites first" order, and no trial was found that tested it in people with cancer.

What the research does contain are specific situations, each with its own logic:

• Strongyloides before immune-suppressing treatment. This is the one widely discussed case where the parasite is dealt with first. The reason is not that the worm hides viruses, but that steroids and other immune-suppressing drugs can turn a silent infection into a fatal one. Reviews and case reports discuss diagnosing and treating it before long-term corticosteroids or transplantation (Nozais and colleagues, 2001; Abad and colleagues, 2022).
• Filarial worms: bacteria first. In the Wolbachia trials, an antibiotic aimed at the worm's bacteria came first, and the antiworm drug later (Mand and colleagues, 2009).
• Salmonella with schistosomiasis. In the 1975 Egyptian series, an antibiotic alone cleared the bacteria from blood and urine during four weeks of follow-up (Farid and colleagues, 1975). No trial in this set compared antibiotic-first with worm-first.
• Trichomonas. Laboratory work suggests the Mycoplasma bacterium inside the parasite may reduce sensitivity to metronidazole (Fürnkranz and colleagues, 2018), while one human study found the parasite's virus made no clinical difference (Graves and colleagues, 2019). No treatment-order trial was found.
• Human immunodeficiency virus with worm infection. Deworming has been tested alongside human immunodeficiency virus care, not instead of or before antiviral treatment, and the measured effect on human immunodeficiency virus markers is small (Means and colleagues, 2016).

Decisions about treating infections, and about cancer treatment, belong with a clinician.

How the Claim Compares With the Research

Supported

• Some parasites do harbor bacteria and viruses. Trichomonas carries Mycoplasma bacteria and its own RNA viruses; Acanthamoeba shelters Legionella and other bacteria; filarial worms depend on Wolbachia bacteria.
• Some parasites make bacterial infections worse or longer-lasting: schistosomiasis has been linked to recurrent Salmonella infection, and Strongyloides hyperinfection carries gut bacteria into the blood.

Supported only in part

• The idea that parasites and other germs stay together as companions fits co-infection research (human immunodeficiency virus with genital schistosomiasis, HTLV-1 with Strongyloides), but in those cases the parasite does not carry the virus. In the HTLV-1 example the virus makes the worm more dangerous.
• The viruses that live inside Trichomonas are described as infecting the parasite itself, and one human study found no clinical effect of them.

Not supported by the research found

• No clinical trial was found that tested treating parasites first in people with several infections, or in people with cancer, and so no published evidence was found that this order gives better antiviral results.
• In the one setting where trials did test a parasite and its bacteria (filarial worms and Wolbachia), the bacteria were treated first.

No research found

• No study was found showing that parasites carry viruses into tumors, or that parasites form part of the tumor microenvironment in people with common cancers. The separate question of microbes inside tumors is covered on Are Parasites Inside Every Tumor?, and the documented parasite-cancer links on Parasites Classified as Cancer-Causing Agents.
• No study was found for parasites blocking oxygen or "poisoning the terrain" as described.

What Is Not Known

• Whether the Mycoplasma bacteria and RNA viruses inside Trichomonas change outcomes for patients in a consistent way; laboratory and human findings do not yet agree.
• How often bacteria sheltered inside Acanthamoeba cause human disease compared with bacteria that reach people directly from water.
• Whether long-term deworming changes human immunodeficiency virus or tuberculosis outcomes such as illness and death; the trials were short or underpowered for these outcomes.
• Whether the link between genital schistosomiasis and human immunodeficiency virus is cause and effect; the main study was cross-sectional.
• Whether the order in which co-existing infections are treated matters outside the specific cases above; no trial was found.
• Whether any of these partnerships plays a role in cancers other than those already linked to specific parasites and viruses.

Connections

• Cancer and Parasites
• Malaria and Burkitt Lymphoma
• Other Suspected Links Between Parasites and Cancer
• How Parasites Can Drive Cancer: The Mechanisms
• Parasites and Heavy Metals
• Strongyloides
• Strongyloides Hyperinfection and Dissemination
• Trichomonas Vaginalis
• Acanthamoeba
• Schistosoma
• Wuchereria Bancrofti
• Onchocerca
• Legionella Pneumophila
• Salmonella
• Mycoplasma
• Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome
• Tuberculosis
• Ivermectin

Key Research Papers

1. Lambertucci JR, Serufo JC, Gerspacher-Lara R, et al. Schistosoma mansoni: assessment of morbidity before and after control. Acta tropica. 2000;77(1):101-9. PubMed PMID: 10996126
2. Farid Z, Bassily S, Mikhail IA, et al. Treatment of chronic enteric fever with amoxicillin. The Journal of infectious diseases. 1975;132(6):698-701. PubMed PMID: 811715
3. Dessì D, Margarita V, Cocco AR, et al. Trichomonas vaginalis and Mycoplasma hominis: new tales of two old friends. Parasitology. 2019;146(9):1150-1155. PubMed PMID: 30616707
4. Margarita V, Congiargiu A, Diaz N, et al. Mycoplasma hominis and Candidatus Mycoplasma girerdii in Trichomonas vaginalis: Peaceful Cohabitants or Contentious Roommates? Pathogens (Basel, Switzerland). 2023;12(9):1083. PubMed PMID: 37764891
5. Margarita V, Fiori PL, Rappelli P. Impact of Symbiosis Between Trichomonas vaginalis and Mycoplasma hominis on Vaginal Dysbiosis: A Mini Review. Frontiers in cellular and infection microbiology. 2020;10:179. PubMed PMID: 32457847
6. Fürnkranz U, Henrich B, Walochnik J. Mycoplasma hominis impacts gene expression in Trichomonas vaginalis. Parasitology research. 2018;117(3):841-847. PubMed PMID: 29368037
7. Kochanowsky JA, Betts EL, Encinas G, et al. Trichomonas vaginalis extracellular vesicles suppress IFNε-mediated responses driven by its intracellular bacterial symbiont Mycoplasma hominis. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(26):e2508297122. PubMed PMID: 40560611
8. Graves KJ, Novak J, Muzny CA. Trichomonas vaginalis Virus: Current Insights and Emerging Perspectives. Viruses. 2025;17(7):898. PubMed PMID: 40733518
9. Graves KJ, Ghosh AP, Schmidt N, et al. Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance. Clinical infectious diseases. 2019;69(12):2170-2176. PubMed PMID: 30768180
10. Greub G, Raoult D. Microorganisms resistant to free-living amoebae. Clinical microbiology reviews. 2004;17(2):413-33. PubMed PMID: 15084508
11. Iovieno A, Ledee DR, Miller D, et al. Detection of bacterial endosymbionts in clinical acanthamoeba isolates. Ophthalmology. 2010;117(3):445-52, 452.e1-3. PubMed PMID: 20031220
12. Okubo T, Matsushita M, Nakamura S, et al. Acanthamoeba S13WT relies on its bacterial endosymbiont to backpack human pathogenic bacteria and resist Legionella infection on solid media. Environmental microbiology reports. 2018;10(3):344-354. PubMed PMID: 29611898
13. Mand S, Pfarr K, Sahoo PK, et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. Am J Trop Med Hyg. 2009;81(4):702-11. PubMed PMID: 19815891
14. Coulibaly YI, Dembele B, Diallo AA, et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med. 2009;361(15):1448-58. PubMed PMID: 19812401
15. Nozais JP, Thellier M, Datry A, et al. [Disseminated strongyloidiasis]. Presse medicale. 2001;30(16):813-8. PubMed PMID: 11388155
16. Abad CLR, Bhaimia E, Schuetz AN, et al. A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation. Clinical transplantation. 2022;36(11):e14795. PubMed PMID: 35987856
17. Meisenheimer Vii J, Dattadeen J, Thomley M, et al. Strongyloides Hyperinfection Syndrome Triggered by a Single Dose of Dexamethasone Administered for Fetal Lung Development. Cureus. 2023;15(9):e46067. PubMed PMID: 37900370
18. Najmuddin A, Hadique S, Parker J. Strongyloides hyperinfection syndrome complications: a case report and review of the literature. The West Virginia medical journal. 2012;108(1):32-8. PubMed PMID: 25134190
19. Ye L, Taylor GP, Rosadas C. Human T-Cell Lymphotropic Virus Type 1 and Strongyloides stercoralis Co-infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2022;9:832430. PubMed PMID: 35237633
20. Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS. 2006;20(4):593-600. PubMed PMID: 16470124
21. Walson JL, Herrin BR, John-Stewart G. Deworming helminth co-infected individuals for delaying HIV disease progression. The Cochrane database of systematic reviews. 2009;(3):CD006419. PubMed PMID: 19588389
22. Means AR, Burns P, Sinclair D, et al. Antihelminthics in helminth-endemic areas: effects on HIV disease progression. The Cochrane database of systematic reviews. 2016;4(4):CD006419. PubMed PMID: 27075622
23. Rafi W, Ribeiro-Rodrigues R, Ellner JJ, et al. 'Coinfection-helminthes and tuberculosis'. Current opinion in HIV and AIDS. 2012;7(3):239-44. PubMed PMID: 22411453

PubMed Topic Searches

1. Trichomonas vaginalis and Mycoplasma hominis symbiosis
2. Acanthamoeba bacterial endosymbionts
3. Wolbachia, doxycycline and filariasis trials
4. Strongyloides hyperinfection and Gram-negative bacteremia
5. Helminth co-infection, HIV and deworming

Featured Videos